Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
Public ClinicalTrials.gov record NCT04670445. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT04670445
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Not applicable
- Lead sponsor
- Massachusetts General Hospital
- Other
- Enrollment
- 210 participants
Conditions and interventions
Conditions
- Advanced Lung Cancer
- Immune Checkpoint Inhibitors
- Immunotherapy
- Small Cell Lung Cancer Extensive Stage
- Stage IV Basal Cell Carcinoma
- Stage IV Bladder Cancer
- Stage IV Breast Cancer
- Stage IV Cervical Cancer
- Stage IV Colorectal Cancer
- Stage IV Cutaneous Squamous Cell Carcinoma
- Stage IV Endometrial Cancer
- Stage IV Esophageal Cancer
- Stage IV Gastric Cancer
- Stage IV Head and Neck Squamous Cell Carcinoma
- Stage IV Hepatocellular Cancer
- Stage IV Melanoma
- Stage IV Merkel Cell Carcinoma
- Stage IV Mesothelioma
- Stage IV Non-Small Cell Lung Cancer
- Stage IV Renal Cell Carcinoma
- Unresectable Non-Small Cell Lung Carcinoma
- Unresectable Stage III Non-Small Cell Lung Cancer
Interventions
- Educational Video and QPL List Other
- Usual Care Other
Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 22, 2021
- Primary completion
- Mar 22, 2023
- Completion
- Mar 31, 2024
- Last update posted
- Oct 22, 2023
2021 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02115 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04670445, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 22, 2023 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04670445 live on ClinicalTrials.gov.